Robb Gary Charles

Corcept Therapeutics Inc.

Chief Business Officer

Avg. Two Year Performance

29% Avg. Purchase Return 14% Compound

(3%) Avg. Sale Return (1%) Compound

Holdings: 32.44K shares

Last Three Months: 23-Aug-24 -- 22-Nov-24

0 Net Amount

Buy:	0	--
Sell:	0	--

Sentiment

Insider Trading Sentiment: Reduce

Company Sentiment

Biotechnology

Drugs

Two Year Chart

23-Nov-22 -- 22-Nov-24

Price ($)

Two Year Stock Price Chart

Sentiment

Company Sentiment

Most Recent Insider Transactions